Keywords: aventis, suffers, pipeline, disappointment, antihypertensive, dropped, decided

Aventis suffers pipeline disappointment as antihypertensive is dropped

Article | 19 August 2002

Aventis has decided to discontinue development of what had once been oneof its most high-profile developmental drug candidates, the antihypertensive 100,240. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Aventis

Aventis Pharma

Bristol-Myers Squibb

Schering Plough

Schering-Plough

Go to company listing

Related Drugs

Allegra

Fexofenadine Hcl

Claritin

Loratadine

Telithromycin

Go to drug listing